+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05423262

Phase III Study Evaluating TRK-950 Alone and with Nivolumab in Advanced Solid Tumors and Melanoma

Led by Toray Industries, Inc · Updated on 2026-10-08

49

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating TRK-950 in patients with advanced solid tumors and melanoma in an open-label phase III study. The study aims to assess the safety and tolerability of TRK-950 alone or in combination with nivolumab in patients with advanced solid tumors, and to evaluate the efficacy of TRK-950 in patients with advanced or recurrent unresectable melanoma who have previously received chemotherapy with dacarbazine and have no standard treatment options. The study includes three parts Part 1 administers two dose levels of TRK-950 to patients with advanced solid tumors refractory or intolerant to standard therapies Part 2 gives two dose levels of TRK-950 combined with nivolumab, with nivolumab dosed at 240 mg intravenously every two weeks Part 3 treats melanoma patients with one dose level of TRK-950. TRK-950 is given intravenously on days 1, 8, 15, and 22 of a 28-day cycle in most parts, with variations in dosing schedules depending on the part and combination with nivolumab. Participants will receive intravenous infusions of study drugs according to their assigned part and dose level. Researchers will monitor safety through dose-limiting toxicities, adverse events, and serious adverse events for up to one year. Pharmacokinetic profiles and antibody development against TRK-950 will be assessed. In Part 3, efficacy will be measured by response rates and survival outcomes over approximately 12 months. The study duration spans from initial dosing through follow-up assessments up to study completion in March 2028.

CONDITIONS

Brief Title

A Study of TRK-950 in Patients With Advanced Solid Tumors

Research Team

T

Toray Contact for Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here